|
|
|
|
|
|
|
HIGHLIGHTS FROM THE 2024 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY ANNUAL MEETING
|
|
|
|
|
|
|
|
SPLASH Trial Highlights Radiopharmaceutical Lutetium-177’s Role in Advanced Prostate Cancer Treatment
|
|
A. Oliver Sartor, MD
|
| Oliver Sartor discusses the SPLASH trial results, evaluating Lutetium-177-PNT2002 in metastatic castration-resistant prostate cancer patients who progressed on ARPI therapy. The study shows significant improvement in radiographic progression-free survival for Lutetium-177-PNT2002 compared to alternate ARPI therapy, with a hazard ratio of 0.71.
|
|
|
|
|
|
|
|
|
|
| Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following Progression on an Androgen-Receptor Pathway Inhibitor (SPLASH)
|
| Oliver Sartor, MD
|
| Oliver Sartor presents interim results from the SPLASH trial, showing that 177Lu-PNT2002 significantly improved radiographic progression-free survival in PSMA-positive mCRPC patients who had progressed on prior androgen-receptor pathway inhibitors. The trial met its primary endpoint, with a median rPFS of 9.5 months for 177Lu-PNT2002 versus 6 months for an alternate ARPI.
|
|
|
|
|
|
| Radium-223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Patients with Bone Metastatic Castration-Resistant Prostate Cancer: First Results of EORTC-GUCG 1333/PEACE-3
|
| Silke Gillessen Sommer, MD
|
| Silke Gillessen presents results from the PEACE-3 trial, which evaluated enzalutamide plus radium-223 in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer. The combination significantly improved radiographic progression-free survival and overall survival, although further analysis is required due to non-proportional hazards.
|
|
|
|
|
|
|
|
|
ARANOTE Study: Transforming Metastatic Hormone Sensitive Prostate Cancer Treatment
|
|
Fred Saad, MD, FRCS
|
| Fred Saad discusses the ARANOTE phase 3 study results, evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. The trial shows significant improvement in radiographic progression-free survival and secondary endpoints, including time to metastatic CRPC and pain progression.
|
|
|
|
|
|
|
|
|
|
| Efficacy and Safety of Darolutamide plus ADT in Patients with mHSPC from the Phase 3 ARANOTE Trial
|
| Fred Saad, MD, FRCSC
|
| Fred Saad presents results from the phase 3 ARANOTE trial, showing that darolutamide plus ADT significantly improved radiological progression-free survival compared to ADT alone in patients with mHSPC. Darolutamide also showed benefits across secondary endpoints, including time to castration-resistant prostate cancer and time to PSA progression, with a favorable safety profile. Based on these findings, darolutamide + ADT without docetaxel should be considered an additional standard of care for mHSPC.
|
|
|
|
|
|
|
|
|
|
|
| Adding Metformin to ADT for Patients with mHSPC: Overall Survival Results from the Multi-Arm, Multi-Stage Randomized Platform Trial STAMPEDE
|
| Silke Gillessen Sommer, MD
|
| Silke Gillessen presented results from the STAMPEDE trial, which evaluated adding metformin to ADT in patients with metastatic hormone-sensitive prostate cancer. The study showed no significant improvement in overall survival with metformin addition in unselected patients, though some benefit was observed in patients with high-volume disease.
|
|
|
|
|
|
| Prostate Cancer Efficacy Results from a Randomized Phase 3 Evaluation of Transdermal Estradiol Versus LHRH Agonists for Androgen Suppression in M0 Prostate Cancer
|
| Ruth Langley, PhD
|
| Ruth Langley presented findings from a phase 3 trial comparing transdermal estradiol (patches) to luteinizing hormone-releasing hormone agonists for androgen suppression in men with high-risk M0 prostate cancer. The trial involved 1,360 men, assessing the non-inferiority of transdermal estradiol for metastasis-free survival compared to LHRH agonists.
|
|
|
|
|
|
| ESMO 2024 Scientific Congress Highlights: Prostate Cancer
|
| Ursula Vogl, MD
|
| At ESMO 2024, key findings in prostate cancer were presented. A phase 3 trial showed that transdermal estradiol was non-inferior to LHRH agonists for androgen suppression in M0 prostate cancer, with fewer cardiovascular side effects and improved bone density, though gynecomastia rates were higher. Additionally, the ARANOTE trial demonstrated that adding darolutamide to ADT in mHSPC patients significantly improved radiographic progression-free survival, while maintaining a favorable safety profile. Further, in the STAMPEDE trial, adding metformin to standard care in mHSPC showed no clear survival benefit, but improved metabolic parameters.
|
|
|
|
|
|
|
|
|
|
|
